Population
In vitro cell models expressing Decay-accelerating factor (DAF) and purified soluble DAF
Comparison
Monoclonal antibody binding to alternate short… vs Absence of alternate SCR-binding antibodies
Design
Preclinical
Authors
Loading...
May caution DAF-targeted therapies or vaccines; hypothesis-generating for antibody-enhanced viral entry and requires human validation.
This study provides the first demonstration that antibody binding to a viral receptor (DAF) can paradoxically enhance viral infectivity.
Shafren et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: